Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An update from Invex Therapeutics Ltd. ( (AU:IXC) ) is now available.
Invex Therapeutics has announced that its 2025 Annual General Meeting will be held in person at Pathways Corporate in Perth on 17 February 2026 at 3:00pm AWST, with the Notice of Meeting and Explanatory Memorandum made available online via the company’s website and the ASX platform. Shareholders are encouraged to lodge their votes by proxy through Automic’s online portal using their securityholder details, and can obtain meeting materials or raise queries electronically, underscoring the company’s continued use of digital channels for governance communications and shareholder engagement.
The most recent analyst rating on (AU:IXC) stock is a Hold with a A$0.12 price target. To see the full list of analyst forecasts on Invex Therapeutics Ltd. stock, see the AU:IXC Stock Forecast page.
More about Invex Therapeutics Ltd.
Invex Therapeutics Ltd is an Australian-listed biopharmaceutical company (ASX: IXC) focused on developing therapies for neurological and related conditions. The company targets unmet medical needs within the therapeutics sector, leveraging clinical and regulatory pathways to bring novel treatments to market for patients in Australia and potentially broader international markets.
Average Trading Volume: 72,000
Technical Sentiment Signal: Strong Buy
Current Market Cap: A$9.77M
For detailed information about IXC stock, go to TipRanks’ Stock Analysis page.